PATHWAYS DRAIN TREATMENT

Informasi Utama

  • Nama dagang:
  • PATHWAYS DRAIN TREATMENT
  • Digunakan untuk:
  • manusia
  • Jenis Obat:
  • Perangkat medis

Dokumen

  • untuk masyarakat umum:
  • Informasi leaflet untuk produk ini saat ini tidak tersedia, Anda dapat mengirim permintaan untuk layanan pelanggan kami dan kami akan memberitahu Anda segera setelah kami mampu mendapatkannya.


    Meminta selebaran informasi untuk masyarakat umum.

Lokalisasi

  • Tersedia di:
  • PATHWAYS DRAIN TREATMENT
    Indonesia
  • Bahasa:
  • Bahasa Indonesia

Informasi lainnya

Status

  • Sumber:
  • Ecolab
  • Nomor Otorisasi:
  • 924913-01
  • Pembaharuan Terakhir:
  • 12-03-2018

Ringkasan karakteristik Produk: dosis, interaksi, efek samping

PATHWAYS DRAIN TREATMENT

Pembersih saluran

LEMBAR DATA KEAMANAN

Nama produk

Penggunaan dan

pembatasan yang

direkomendasikan

Nomor telepon darurat

:

:

Informasi pemasok

:

PATHWAYS DRAIN TREATMENT

Gunakan hanya untuk tujuan pada label produk.

:

Bagian 1. Identifikasi produk kimia dan perusahaan

Nama-nama lain

:

Tidak ada.

Informasi pengenceran

produk

:

0.03%

PT. Ecolab Indonesia

Jl. Jababeka XII Kav V-37

Kawasan Industri jababeka, Cikarang

Indonesia 17350

Tel : (62-21) 5707557 Fax : (62-21) 5707682

+1 651-222-5352

Tidak diklasifikasikan.

Klasifikasi GHS

(Globally

Harmonised System

~ Sistim Harmonisasi

Global)

:

Kata sinyal

:

Tanpa Kata Sinyal

Pernyataan bahaya

:

Tidak diketahui efek signifikan atau bahaya

kritis.

Pernyataan kehati-hatian

Pencegahan

:

Cuci sepenuhnya sesudah penanganan.

Tanggapan

:

Tidak berlaku.

Penyimpanan

:

Tidak teridentifikasi adanya tindakan khusus

lainnya.

Pembuangan

:

Tidak berlaku.

Bahaya lain

:

Tidak diketahui.

2. Identifikasi Bahaya

Elemen label GHS

Produk TERJUAL

Penggunaan produk dicairkan

Tidak diklasifikasikan.

Tanpa Kata Sinyal

Tidak diketahui efek signifikan atau bahaya

kritis.

Cuci sepenuhnya sesudah penanganan.

Tidak berlaku.

Tidak teridentifikasi adanya tindakan khusus

lainnya.

Tidak berlaku.

Tidak diketahui.

Campuran

3. Komposisi/ Informasi tentang Bahan Penyusun Senyawa tunggal

Zat/sediaan

:

Tidak terdapat bahan yang, sejauh pengetahuan pemasok saat ini dan pada konsentrasi yang berlaku,

diklasifikasikan sebagai berbahaya pada kesehatan atau lingkungan dan karenanya diperlukan pelaporan dalam

bagian ini.

924913-01

Halaman: 1/6

PATHWAYS DRAIN TREATMENT

Dapatkan pertolongan medis jika terjadi gejala.

Efek setelah terkena mata tidak diketahui. Bilas

dengan air selama beberapa menit.

Efek setelah terkena kulit tidak diketahui. Bilas

dengan air selama beberapa menit.

Tidak perlu tindakan khusus. Obati berdasarkan

gejala.

Kontak mata

Kontak kulit

Penghirupan

Tertelan

:

:

:

:

Perlindungan bagi

penolong pertama

:

Tidak boleh melakukan tindakan yang menyangkut risiko pribadi atau tanpa pelatihan yang

sesuai.

Catatan untuk

dokter

:

Obati berdasarkan gejala. Segera menghubungi ahli perawatan racun jika jumlah besar

termakan atau terhirup.

Lihat informasi toksikologi (bagian 11)

4. Tindakan Pertolongan Pertama

Produk TERJUAL

Penggunaan produk dicairkan

Efek setelah terkena mata tidak diketahui.

Bilas dengan air selama beberapa menit.

Efek setelah terkena kulit tidak diketahui.

Bilas dengan air selama beberapa menit.

Tidak perlu tindakan khusus. Obati

berdasarkan gejala.

Dapatkan pertolongan medis jika terjadi

gejala.

Jika ada kebakaran segera isolasi tempat kejadian dengan menjauhkan semua

orang dari lokasi kebakaran. Tidak boleh melakukan tindakan yang menyangkut

risiko pribadi atau tanpa pelatihan yang sesuai.

Produk dekomposisi termal

berbahaya

Bahaya spesifik yang

diakibatkan bahan kimia

tersebut

Bahan-bahan berikut ini mungkin dapat termasuk golongan produk penguraian-

hayati:

karbon dioksida

karbon monoksida

Dalam kebakaran atau jika dipanaskan, peningkatan tekanan akan terjadi dan

wadah bisa meledak.

Petugas pemadam kebakaran harus memakai perlengkapan pelindung yang

memadai dan alat bantu pernapasan (Self-Contained Breathing Apparatus - SCBA)

yang berpelindung-wajah penuh dan yang beroperasi dalam mode tekanan positif.

Alat pelindung khusus

untuk petugas pemadam

kebakaran

Gunakan semprotan air, kabut atau busa.

:

:

:

Media yang sesuai untuk

pemadaman kebakaran

:

:

5. Tindakan Pemadaman Kebakaran

Produk TERJUAL

Langkah-langkah

pencegahan bagi

lingkungan

Tindakan

pencegahan pribadi

:

:

Gunakan alat pelindung diri sesuai kebutuhan.

Jaga agar tumpahan bahan dalam jumlah

banyak tidak mengalir ke tanah dan saluran air di

permukaan tanah.

Gunakan air bilas untuk pembersihan akhir.

Metode untuk

membersihan

:

6. Tindakan Penanggulangan jika terjadi Kebocoran

Produk TERJUAL

Penggunaan produk dicairkan

Gunakan alat pelindung diri sesuai

kebutuhan.

Jaga agar tumpahan bahan dalam jumlah

banyak tidak mengalir ke tanah dan saluran

air di permukaan tanah.

Gunakan air bilas untuk pembersihan akhir.

Menangani/

Penanganan

Penyimpanan

Cuci sepenuhnya sesudah penanganan.

Jauhkan dari jangkauan anak-anak.

:

:

7. Penanganan dan Penyimpanan

Produk TERJUAL

Penggunaan produk dicairkan

Cuci sepenuhnya sesudah penanganan.

Jauhkan dari jangkauan anak-anak.

924913-01

Halaman: 2/6

PATHWAYS DRAIN TREATMENT

7. Penanganan dan Penyimpanan

Simpan dalam suhu antara: 0 dan 50°C

Perlindungan

tangan

Tidak diperlukan respirator dalam kondisi normal

dan kondisi yang ditentukan untuk penggunaan

produk.

Tidak ada peralatan pelindung yang dibutuhkan

dalam kondisi pemakaian normal.

Tidak ada peralatan pelindung yang dibutuhkan

dalam kondisi pemakaian normal.

Perlindungam mata

Perlindungan

pernapasan

:

:

:

Perlindungan kulit

Tidak ada peralatan pelindung yang dibutuhkan

dalam kondisi pemakaian normal.

:

Pengendalian teknik

yang sesuai

:

Ventilasi umum yang baik semestinya cukup

untuk mengendalikan pemaparan pekerja

terhadap kadar kontaminasi yang terbawa-udara.

Cuci tangan sebelum makan, minum atau merokok.

Tindakan higienis

:

Parameter pengendalian

Perlindungan perorangan

8. Kontrol Paparan/Perlindungan Diri

Produk TERJUAL

Penggunaan produk dicairkan

Ventilasi umum yang baik semestinya cukup

untuk mengendalikan pemaparan pekerja

terhadap kadar kontaminasi yang terbawa-

udara.

Tidak ada peralatan pelindung yang

dibutuhkan dalam kondisi pemakaian normal.

Tidak ada peralatan pelindung yang

dibutuhkan dalam kondisi pemakaian normal.

Tidak diperlukan respirator dalam kondisi

normal dan kondisi yang ditentukan untuk

penggunaan produk.

Tidak ada.

Nama bahan

Batas pemaparan

Tidak ada peralatan pelindung yang

dibutuhkan dalam kondisi pemakaian normal.

Bentuk fisik

Titik lebur

Tekanan uap

Kerapatan relatif

Rapat uap

Kelarutan

Cairan.

Tidak tersedia.

1 (Air = 1)

Tidak tersedia.

Tidak tersedia.

Dengan mudah dapat larut pada bahan-bahan

berikut: air dingin dan air panas.

sitrus

Bau

pH

Hijau [Terang]

Warna

Laju penguapan

(butil asetat = 1)

Tidak tersedia.

Suhu dapat

membakar sendiri

(auto-ignition)

Titik nyala

Tidak tersedia.

> 100°C

Tidak tersedia.

7.5 (100%)

Koefisien partisi (n-

oktanol/air)

:

:

:

:

:

:

:

:

:

:

:

:

:

Titik didih

:

Tidak tersedia.

Flamabilitas

(padatan, gas)

:

Tidak tersedia.

Batas ledakan

:

Tidak tersedia.

9. Sifat Fisika dan Kimia

Produk TERJUAL

Penggunaan produk dicairkan

Cairan.

Bening.

Tidak berbau

7.22

> 100°C

924913-01

Halaman: 3/6

PATHWAYS DRAIN TREATMENT

9. Sifat Fisika dan Kimia

Kekentalan

Tidak tersedia.

:

Suhu penguraian

Ambang bau

:

:

Tidak tersedia.

Tidak tersedia.

Hasil peruraian yang

berbahaya

Kondisi untuk dihindarkan

Tidak ada data khusus.

Pada kondisi penyimpanan dan penggunaan yang normal, produk-produk

penguraian-hayati yang berbahaya seharusnya tidak terproduksi.

Produk ini stabil.

Stabilitas

Tidak tersedia.

:

:

:

Bahan untuk dihindari

:

Kemungkinan reaksi yang

berbahaya

:

Dibawah kondisi penyimpanan dan penggunaan yang normal, reaksi yang

berbahaya tidak akan terjadi.

10. Stabilitas dan Reaktifitas

Produk TERJUAL

Data toksisitas

Nama produk/bahan

Hasil

Spesies

Dosis

Tidak diketahui efek signifikan atau bahaya kritis.

Karsinogenisitas

:

Tidak diketahui efek signifikan atau bahaya kritis.

Mutagenisitas

:

Tidak diketahui efek signifikan atau bahaya kritis.

Teratogenisitas

:

Efek-efek perkembangan

selama masa pertumbuhan

:

Tidak diketahui efek signifikan atau bahaya kritis.

Efek-efek kesuburan

:

Tidak diketahui efek signifikan atau bahaya kritis.

Toksisitas kronis

Rute Paparan

:

Kontak kulit, Kontak mata, Penghirupan, Tertelan

Toksisitas akut

Penghirupan

:

Tidak diketahui efek signifikan atau bahaya kritis.

Tidak diketahui efek signifikan atau bahaya kritis.

:

Tertelan

Kontak kulit

:

Tidak diketahui efek signifikan atau bahaya kritis.

Tidak diketahui efek signifikan atau bahaya kritis.

:

Kontak mata

11. Informasi Toksikologi

Gejala

Kontak kulit

Tertelan

Penghirupan

Tidak ada data khusus.

Tidak ada data khusus.

Tidak ada data khusus.

:

:

:

Kontak mata

:

Tidak ada data khusus.

Produk TERJUAL

Penggunaan produk dicairkan

Tidak ada data khusus.

Tidak ada data khusus.

Tidak ada data khusus.

Tidak ada data khusus.

Tidak diketahui efek signifikan atau bahaya

kritis.

Tidak diketahui efek signifikan atau bahaya

kritis.

Tidak diketahui efek signifikan atau bahaya

kritis.

Tidak diketahui efek signifikan atau bahaya

kritis.

Tidak tersedia.

924913-01

Halaman: 4/6

PATHWAYS DRAIN TREATMENT

Mobilitas dalam tanah

Tidak tersedia.

:

Efek merugikan lainnya

:

Tidak diketahui efek signifikan atau bahaya kritis.

Efek keracunan pada organisme air dan darat

Nama produk/bahan

Spesies

Hasil

Pemaparan

Persistensi dan kemudahan terurai

Nama produk/bahan

Uji

Dosis

Hasil

Zat inokulasi

Ekotoksisitas

:

Tidak diketahui efek signifikan atau bahaya kritis.

12. Informasi Ekologi

Produk TERJUAL

Tidak tersedia.

Tidak tersedia.

Produk diencerkan dapat disalurkan ke saluran

pembuangan sanitasi Buang kemasan kosong di

tempat sampah

:

Metode

pembuangan

13. Pertimbangan Pembuangan/Pemusnahan

Produk TERJUAL

Penggunaan produk dicairkan

Produk diencerkan dapat disalurkan ke

saluran pembuangan sanitasi Buang

kemasan kosong di tempat sampah

Nomor PBB Nama pengapalan yang sesuai

Penggolongan

Informasi

pengaturan

PG*

Informasi tambahan

PG* : Kelompok pengemasan

Lihat dokumen pengapalan untuk informasi transportasi tertentu.

14. Informasi Transportasi

Produk TERJUAL

Penggunaan produk dicairkan

Tidak dimaksudkan untuk

transportasi.

Kelas ADR/RID

Tidak diatur.

Kelas IMDG

Tidak diatur

15. Informasi yang berkaitan dengan Regulasi

Regulasi tentang

lingkungan, kesehatan

dan keamanan untuk

produk tersebut

:

Produk TERJUAL

Penggunaan produk dicairkan

Sejauh diketahui tidak ada peraturan nasional

atau kedaerahan spesifik yang berlaku untuk

produk ini (termasuk bahan-bahan produk

tersebut).

Sejauh diketahui tidak ada peraturan

nasional atau kedaerahan spesifik yang

berlaku untuk produk ini (termasuk bahan-

bahan produk tersebut).

Sejarah / Riwayat

Tanggal terbitan

Tanggal terbitan

sebelumnya

:

:

16. Informasi Lain

Referensi

Disiapkan oleh

:

Urusan peraturan

14 Jun 2013

Tidak ada validasi sebelumnya

924913-01

Halaman: 5/6

PATHWAYS DRAIN TREATMENT

16. Informasi Lain

Informasi di atas diyakini benar sehubungan dengan formula yang digunakan untuk memproduksi produk di

negara asal. Sebagai data, standar, dan perubahan peraturan, dan ketentuan penggunaan dan penanganan

berada di luar kendali kami, TIDAK ADA GARANSI, TERSURAT MAUPUN TERSIRAT, DIBUAT SEBAGAI

KELENGKAPAN ATAU AKURASI LANJUTAN DARI INFORMASI INI.

Pemberitahuan kepada pembaca

Tidak tersedia.

924913-01

Halaman: 6/6

19-2-2019

Statement from FDA Commissioner Scott Gottlieb, M.D., and Director of FDA’s Center for Biologics Evaluation and Research Peter Marks, M.D., Ph.D., cautioning consumers against receiving young donor plasma infusions that are promoted as unproven treatment

Statement from FDA Commissioner Scott Gottlieb, M.D., and Director of FDA’s Center for Biologics Evaluation and Research Peter Marks, M.D., Ph.D., cautioning consumers against receiving young donor plasma infusions that are promoted as unproven treatment

FDA statement cautioning consumers against receiving young donor plasma infusions that are promoted as unproven treatment for varying conditions

FDA - U.S. Food and Drug Administration

14-2-2019

FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices

FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices

FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices

FDA - U.S. Food and Drug Administration

8-2-2019


Draft guideline on clinical investigation of medicinal products for the treatment of gout

Draft guideline on clinical investigation of medicinal products for the treatment of gout

Draft guideline on clinical investigation of medicinal products for the treatment of gout

Europe - EMA - European Medicines Agency

6-2-2019

FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder

FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder

FDA approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening disorder that causes blood clotting.

FDA - U.S. Food and Drug Administration

30-1-2019

FDA approves first generic Advair Diskus

FDA approves first generic Advair Diskus

FDA approved the first generic of Advair Diskus for treatment of asthma and maintenance treatment of airflow obstruction and reducing exacerbations with COPD.

FDA - U.S. Food and Drug Administration

14-1-2019


Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - Revision 3

Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - Revision 3

Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - Revision 3

Europe - EMA - European Medicines Agency

12-1-2019

Pest categorisation of Pseudopityophthorus minutissimus and P. pruinosus

Pest categorisation of Pseudopityophthorus minutissimus and P. pruinosus

Published on: Fri, 11 Jan 2019 The Panel on Plant Health performed a pest categorisation of Pseudopityophthorus minutissimus and Pseudopityophthorus pruinosus, two well‐defined insect species in the family Curculionidae, subfamily Scolytinae (Insecta: Coleoptera). They can be identified using taxonomic keys. P. minutissimus is present in parts of Canada and the USA, and P. pruinosus is present in parts of the USA, Guatemala, Honduras and Mexico. The main host plants of the two species are Quercus spp., ...

Europe - EFSA - European Food Safety Authority EFSA Journal

8-1-2019

Happy Together, Inc. Issues Voluntary Nationwide Recall of Product Due to Presence of Undeclared Sildenafil and Tadalafil

Happy Together, Inc. Issues Voluntary Nationwide Recall of Product Due to Presence of Undeclared Sildenafil and Tadalafil

Happy Together, Inc. Boynton Beach, FL is voluntarily recalling all lots within expiry of the Rhino 5k capsules to the consumer level. FDA analysis founds these products to be tainted with sildenafil and Tadalafil. Sildenafil/Tadalafil is an FDA approved drug for the treatment of erectile dysfunction, the presence of sildenafil in the Rhino 5k products renders them unapproved drugs for which safety and efficacy have not been established, therefor subject to recall.

FDA - U.S. Food and Drug Administration

8-1-2019

Antimicrobial resistance

Antimicrobial resistance

Antimicrobial resistance is a major international human and animal health issue, because the emergence and spread of drug-resistant strains of bacteria call into question the efficacy of these treatments in humans and animals alike. Preserving the effectiveness of antibiotics is therefore a genuine public health challenge requiring an integrated approach across all types of medicine, according to the "One Health" concept covering both humans and animals. ANSES has mobilised significant resources to addr...

France - Agence Nationale du Médicament Vétérinaire

20-2-2019


Orphan designation: Histamine dihydrochloride, Treatment of acute myeloid leukaemia, 11/04/2005, Expired

Orphan designation: Histamine dihydrochloride, Treatment of acute myeloid leukaemia, 11/04/2005, Expired

Orphan designation: Histamine dihydrochloride, Treatment of acute myeloid leukaemia, 11/04/2005, Expired

Europe - EMA - European Medicines Agency

20-2-2019


Orphan designation: miglustat, Treatment of Niemann-Pick disease, type C, 16/02/2006, Expired

Orphan designation: miglustat, Treatment of Niemann-Pick disease, type C, 16/02/2006, Expired

Orphan designation: miglustat, Treatment of Niemann-Pick disease, type C, 16/02/2006, Expired

Europe - EMA - European Medicines Agency

20-2-2019


Orphan designation: azacitidine, Treatment of myelodysplastic syndromes, 06/02/2002, Expired

Orphan designation: azacitidine, Treatment of myelodysplastic syndromes, 06/02/2002, Expired

Orphan designation: azacitidine, Treatment of myelodysplastic syndromes, 06/02/2002, Expired

Europe - EMA - European Medicines Agency

20-2-2019


Orphan designation: azacitidine, Treatment of acute myeloid leukaemia, 29/11/2007, Expired

Orphan designation: azacitidine, Treatment of acute myeloid leukaemia, 29/11/2007, Expired

Orphan designation: azacitidine, Treatment of acute myeloid leukaemia, 29/11/2007, Expired

Europe - EMA - European Medicines Agency

20-2-2019


Orphan designation: Rufinamide, Treatment of Lennox-Gastaut syndrome, 20/10/2004, Expired

Orphan designation: Rufinamide, Treatment of Lennox-Gastaut syndrome, 20/10/2004, Expired

Orphan designation: Rufinamide, Treatment of Lennox-Gastaut syndrome, 20/10/2004, Expired

Europe - EMA - European Medicines Agency

20-2-2019


Orphan designation: Recombinant megakaryopoiesis-stimulating protein, Treatment of idiopathic thrombocytopenic purpura, 27/05/2005, Expired

Orphan designation: Recombinant megakaryopoiesis-stimulating protein, Treatment of idiopathic thrombocytopenic purpura, 27/05/2005, Expired

Orphan designation: Recombinant megakaryopoiesis-stimulating protein, Treatment of idiopathic thrombocytopenic purpura, 27/05/2005, Expired

Europe - EMA - European Medicines Agency

20-2-2019


Orphan designation: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand, The treatment of pancreatic cancer, 19/11/2018, Positive

Orphan designation: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand, The treatment of pancreatic cancer, 19/11/2018, Positive

Orphan designation: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand, The treatment of pancreatic cancer, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: Larotrectinib, Treatment of glioma, 19/11/2018, Positive

Orphan designation: Larotrectinib, Treatment of glioma, 19/11/2018, Positive

Orphan designation: Larotrectinib, Treatment of glioma, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: fidanacogene elaparvovec, Treatment of haemophilia B, 19/11/2018, Positive

Orphan designation: fidanacogene elaparvovec, Treatment of haemophilia B, 19/11/2018, Positive

Orphan designation: fidanacogene elaparvovec, Treatment of haemophilia B, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: apraglutide, Treatment of short bowel syndrome, 19/11/2018, Positive

Orphan designation: apraglutide, Treatment of short bowel syndrome, 19/11/2018, Positive

Orphan designation: apraglutide, Treatment of short bowel syndrome, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: 4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid, Treatment of cystic fibrosis, 19/11/2014, Positive

Orphan designation: 4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid, Treatment of cystic fibrosis, 19/11/2014, Positive

Orphan designation: 4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid, Treatment of cystic fibrosis, 19/11/2014, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: human apotransferrin, Treatment of beta-thalassaemia intermedia and major, 19/11/2018, Positive

Orphan designation: human apotransferrin, Treatment of beta-thalassaemia intermedia and major, 19/11/2018, Positive

Orphan designation: human apotransferrin, Treatment of beta-thalassaemia intermedia and major, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: Glucagon, Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome, 19/11/2018, Positive

Orphan designation: Glucagon, Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome, 19/11/2018, Positive

Orphan designation: Glucagon, Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate, Treatment of cystic fibrosis, 19/11/2018, Positive

Orphan designation: cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate, Treatment of cystic fibrosis, 19/11/2018, Positive

Orphan designation: cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate, Treatment of cystic fibrosis, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: propagermanium, Treatment of focal segmental glomerulosclerosis, 19/11/2018, Positive

Orphan designation: propagermanium, Treatment of focal segmental glomerulosclerosis, 19/11/2018, Positive

Orphan designation: propagermanium, Treatment of focal segmental glomerulosclerosis, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: 3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid, Treatment of ATTR amyloidosis, 19/11/2018, Positive

Orphan designation: 3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid, Treatment of ATTR amyloidosis, 19/11/2018, Positive

Orphan designation: 3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid, Treatment of ATTR amyloidosis, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride, Treatment of Kabuki syndrome, 19/11/2018, Positive

Orphan designation: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride, Treatment of Kabuki syndrome, 19/11/2018, Positive

Orphan designation: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride, Treatment of Kabuki syndrome, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: Rucaparib, Treatment of ovarian cancer, 10/10/2012, Withdrawn

Orphan designation: Rucaparib, Treatment of ovarian cancer, 10/10/2012, Withdrawn

Orphan designation: Rucaparib, Treatment of ovarian cancer, 10/10/2012, Withdrawn

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: Salmonella typhi Ty21a strain transfected with a plasmid vector encoding the human vascular endothelial growth factor receptor 2, Treatment of glioma, 23/08/2017, Positive

Orphan designation: Salmonella typhi Ty21a strain transfected with a plasmid vector encoding the human vascular endothelial growth factor receptor 2, Treatment of glioma, 23/08/2017, Positive

Orphan designation: Salmonella typhi Ty21a strain transfected with a plasmid vector encoding the human vascular endothelial growth factor receptor 2, Treatment of glioma, 23/08/2017, Positive

Europe - EMA - European Medicines Agency

15-2-2019

#ICYMI: FDA authorizes first interoperable insulin pump intended to  allow patients to customize treatment through their individual diabetes  management devices. Read more here:  https://go.usa.gov/xEUuM   #MedicalDevice #FDA

#ICYMI: FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices. Read more here: https://go.usa.gov/xEUuM  #MedicalDevice #FDA

#ICYMI: FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices. Read more here: https://go.usa.gov/xEUuM  #MedicalDevice #FDA

FDA - U.S. Food and Drug Administration

13-2-2019


Orphan designation: Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase, Treatment of ornithine transcarbamylase deficiency, 20/03/2017, Positive

Orphan designation: Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase, Treatment of ornithine transcarbamylase deficiency, 20/03/2017, Positive

Orphan designation: Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase, Treatment of ornithine transcarbamylase deficiency, 20/03/2017, Positive

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: Imlifidase, Treatment of anti-glomerular basement membrane disease, 19/11/2018, Positive

Orphan designation: Imlifidase, Treatment of anti-glomerular basement membrane disease, 19/11/2018, Positive

Orphan designation: Imlifidase, Treatment of anti-glomerular basement membrane disease, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: Agammaglobulinaemia tyrosine kinase, Treatment of pemphigus, 12/12/2017, Positive

Orphan designation: Agammaglobulinaemia tyrosine kinase, Treatment of pemphigus, 12/12/2017, Positive

Orphan designation: Agammaglobulinaemia tyrosine kinase, Treatment of pemphigus, 12/12/2017, Positive

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide, Treatment of acute myeloid leukaemia, 14/10/2016, Positive

Orphan designation: P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide, Treatment of acute myeloid leukaemia, 14/10/2016, Positive

Orphan designation: P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide, Treatment of acute myeloid leukaemia, 14/10/2016, Positive

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide, Treatment of cystic fibrosis, 21/05/2015, Positive

Orphan designation: 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide, Treatment of cystic fibrosis, 21/05/2015, Positive

Orphan designation: 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide, Treatment of cystic fibrosis, 21/05/2015, Positive

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: Humanised single-chain monoclonal antibody against CD37 (otlertuzumab), Treatment chronic lymphocytic leukaemia, 06/12/2012, Positive

Orphan designation: Humanised single-chain monoclonal antibody against CD37 (otlertuzumab), Treatment chronic lymphocytic leukaemia, 06/12/2012, Positive

Orphan designation: Humanised single-chain monoclonal antibody against CD37 (otlertuzumab), Treatment chronic lymphocytic leukaemia, 06/12/2012, Positive

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: Seladelpar, Treatment of primary biliary cholangitis, 16/10/2017, Positive

Orphan designation: Seladelpar, Treatment of primary biliary cholangitis, 16/10/2017, Positive

Orphan designation: Seladelpar, Treatment of primary biliary cholangitis, 16/10/2017, Positive

Europe - EMA - European Medicines Agency

1-2-2019


First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes

First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes

First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes

Europe - EMA - European Medicines Agency

28-1-2019


Orphan designation: Pegylated B-domain-deleted sequence-modified recombinant human factor VIII (damoctocog alfa pegol), Treatment of haemophilia A, 23/02/2011, Positive

Orphan designation: Pegylated B-domain-deleted sequence-modified recombinant human factor VIII (damoctocog alfa pegol), Treatment of haemophilia A, 23/02/2011, Positive

Orphan designation: Pegylated B-domain-deleted sequence-modified recombinant human factor VIII (damoctocog alfa pegol), Treatment of haemophilia A, 23/02/2011, Positive

Europe - EMA - European Medicines Agency

28-1-2019


Orphan designation: Mogamulizumab, Treatment of cutaneous T-cell lymphoma, 14/10/2016, Positive

Orphan designation: Mogamulizumab, Treatment of cutaneous T-cell lymphoma, 14/10/2016, Positive

Orphan designation: Mogamulizumab, Treatment of cutaneous T-cell lymphoma, 14/10/2016, Positive

Europe - EMA - European Medicines Agency

25-1-2019


Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, Positive

Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, Positive

Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, Positive

Europe - EMA - European Medicines Agency

25-1-2019


Orphan designation: Glucagon, Treatment of congenital hyperinsulinism, 08/10/2009, Positive

Orphan designation: Glucagon, Treatment of congenital hyperinsulinism, 08/10/2009, Positive

Orphan designation: Glucagon, Treatment of congenital hyperinsulinism, 08/10/2009, Positive

Europe - EMA - European Medicines Agency

25-1-2019


Orphan designation: Mannitolum, Treatment of cystic fibrosis, 07/11/2005, Positive

Orphan designation: Mannitolum, Treatment of cystic fibrosis, 07/11/2005, Positive

Orphan designation: Mannitolum, Treatment of cystic fibrosis, 07/11/2005, Positive

Europe - EMA - European Medicines Agency

25-1-2019


Orphan designation: Triamcinolone acetonide, Treatment of non-infectious uveitis, 21/05/2015, Positive

Orphan designation: Triamcinolone acetonide, Treatment of non-infectious uveitis, 21/05/2015, Positive

Orphan designation: Triamcinolone acetonide, Treatment of non-infectious uveitis, 21/05/2015, Positive

Europe - EMA - European Medicines Agency

23-1-2019


Orphan designation: Allogeneic ex-vivo-expanded umbilical cord blood-derived haematopoietic CD34+ progenitor cells and allogeneic non-expanded umbilical cord blood-derived haematopoietic mature myeloid and lymphoid cells, Treatment in haematopoietic stem

Orphan designation: Allogeneic ex-vivo-expanded umbilical cord blood-derived haematopoietic CD34+ progenitor cells and allogeneic non-expanded umbilical cord blood-derived haematopoietic mature myeloid and lymphoid cells, Treatment in haematopoietic stem

Orphan designation: Allogeneic ex-vivo-expanded umbilical cord blood-derived haematopoietic CD34+ progenitor cells and allogeneic non-expanded umbilical cord blood-derived haematopoietic mature myeloid and lymphoid cells, Treatment in haematopoietic stem cell transplantation, 20/03/2017, Positive

Europe - EMA - European Medicines Agency

23-1-2019


Orphan designation: Octreotide acetate (oral use), Treatment of acromegaly, 05/08/2013, Positive

Orphan designation: Octreotide acetate (oral use), Treatment of acromegaly, 05/08/2013, Positive

Orphan designation: Octreotide acetate (oral use), Treatment of acromegaly, 05/08/2013, Positive

Europe - EMA - European Medicines Agency

23-1-2019


Orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride-, Treatment of diffuse large B-cell lymphoma, 27/06/2016, Positive

Orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride-, Treatment of diffuse large B-cell lymphoma, 27/06/2016, Positive

Orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride-, Treatment of diffuse large B-cell lymphoma, 27/06/2016, Positive

Europe - EMA - European Medicines Agency

23-1-2019


Orphan designation: Humanised anti-IL-6 receptor monoclonal antibody, Treatment of neuromyelitis optica spectrum disorders, 27/06/2016, Positive

Orphan designation: Humanised anti-IL-6 receptor monoclonal antibody, Treatment of neuromyelitis optica spectrum disorders, 27/06/2016, Positive

Orphan designation: Humanised anti-IL-6 receptor monoclonal antibody, Treatment of neuromyelitis optica spectrum disorders, 27/06/2016, Positive

Europe - EMA - European Medicines Agency

23-1-2019


No new patients should start treatment with Lartruvo after study shows cancer medicine does not prolong life

No new patients should start treatment with Lartruvo after study shows cancer medicine does not prolong life

No new patients should start treatment with Lartruvo after study shows cancer medicine does not prolong life

Europe - EMA - European Medicines Agency

22-1-2019


Orphan designation: 17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione, Treatment of Duchenne muscular dystrophy, 22/08/2014, Positive

Orphan designation: 17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione, Treatment of Duchenne muscular dystrophy, 22/08/2014, Positive

Orphan designation: 17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione, Treatment of Duchenne muscular dystrophy, 22/08/2014, Positive

Europe - EMA - European Medicines Agency

22-1-2019


Orphan designation: Moxetumomab pasudotox, Treatment of B-lymphoblastic leukaemia / lymphoma, 17/07/2013, Positive

Orphan designation: Moxetumomab pasudotox, Treatment of B-lymphoblastic leukaemia / lymphoma, 17/07/2013, Positive

Orphan designation: Moxetumomab pasudotox, Treatment of B-lymphoblastic leukaemia / lymphoma, 17/07/2013, Positive

Europe - EMA - European Medicines Agency

22-1-2019


Orphan designation: Doxorubicin hydrochloride (in heat-sensitive liposomes), Treatment of hepatocellular carcinoma, 23/02/2011, Positive

Orphan designation: Doxorubicin hydrochloride (in heat-sensitive liposomes), Treatment of hepatocellular carcinoma, 23/02/2011, Positive

Orphan designation: Doxorubicin hydrochloride (in heat-sensitive liposomes), Treatment of hepatocellular carcinoma, 23/02/2011, Positive

Europe - EMA - European Medicines Agency

22-1-2019


Orphan designation: Chimeric monoclonal antibody against GD2, Treatment of neuroblastoma, 08/11/2012, Positive

Orphan designation: Chimeric monoclonal antibody against GD2, Treatment of neuroblastoma, 08/11/2012, Positive

Orphan designation: Chimeric monoclonal antibody against GD2, Treatment of neuroblastoma, 08/11/2012, Positive

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec), Treatment of retinitis pigmentosa, 28/07/2015, Positive

Orphan designation: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec), Treatment of retinitis pigmentosa, 28/07/2015, Positive

Orphan designation: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec), Treatment of retinitis pigmentosa, 28/07/2015, Positive

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec), Treatment of leber's congenital amaurosis, 02/04/2012, Positive

Orphan designation: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec), Treatment of leber's congenital amaurosis, 02/04/2012, Positive

Orphan designation: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec), Treatment of leber's congenital amaurosis, 02/04/2012, Positive

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: Autologous skeletal myoblasts expanded ex vivo, Treatment of oculopharyngeal muscular dystrophy, 13/04/2018, Negative

Orphan designation: Autologous skeletal myoblasts expanded ex vivo, Treatment of oculopharyngeal muscular dystrophy, 13/04/2018, Negative

Orphan designation: Autologous skeletal myoblasts expanded ex vivo, Treatment of oculopharyngeal muscular dystrophy, 13/04/2018, Negative

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant, Treatment of haemophilia B, 26/10/2018, Positive

Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant, Treatment of haemophilia B, 26/10/2018, Positive

Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant, Treatment of haemophilia B, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, Treatment of medullary thyroid carcinoma, 26/10/2018, Positive

Orphan designation: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, Treatment of medullary thyroid carcinoma, 26/10/2018, Positive

Orphan designation: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, Treatment of medullary thyroid carcinoma, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid, Treatment of dermatomyositis, , Positive

Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid, Treatment of dermatomyositis, , Positive

Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid, Treatment of dermatomyositis, , Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: Recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII, Treatment of haemophilia

Orphan designation: Recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII, Treatment of haemophilia

Orphan designation: Recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII, Treatment of haemophilia A, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment

Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment

Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment of maple syrup urine disease, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: gefinitib, Treatment of Fanconi anaemia type A, 26/10/2018, Positive

Orphan designation: gefinitib, Treatment of Fanconi anaemia type A, 26/10/2018, Positive

Orphan designation: gefinitib, Treatment of Fanconi anaemia type A, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG, Treatment of multiple myeloma, 26/10/2018, Positive

Orphan designation: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG, Treatment of multiple myeloma, 26/10/2018, Positive

Orphan designation: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG, Treatment of multiple myeloma, 26/10/2018, Positive

Europe - EMA - European Medicines Agency